Biophytis SA (ALBPS) AI Stock Analysis

• Market Cap: €2.66M
• Dividend Yield: N/A
• Average Volume (3M): 346.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: FR
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 42,118,282
• 10 Day Avg. Volume: 335,651
• 30 Day Avg. Volume: 346,065
• PEG Ratio: <0.01
• Price to Book (P/B): -0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: €0.06 ▲(5.00% Upside)

The score is primarily constrained by weak financial fundamentals—no revenue, ongoing losses, negative equity, and continued cash burn despite 2024 improvement. Technicals add modest downside bias with bearish MACD and the stock below key longer-term moving averages, while valuation offers limited insight because earnings are negative and there is no dividend yield support.

Positive Factors

Focused clinical-stage specialization

Specialization in age-related diseases and muscle-function therapeutics indicates a focused R&D strategy and domain expertise. A concentrated pipeline can create differentiated assets, streamline trial design and partner appeal, supporting durable value creation if clinical progress continues.

Improving loss and cash-burn trends

Material narrowing of losses and reduced cash outflows in 2024 signals better cost control and operational discipline. Sustained improvements enhance runway and lower near-term financing pressure, increasing the company’s ability to reach clinical inflection points before further dilution.

Partial debt reduction since 2022

Measured reduction in debt improves balance-sheet flexibility and reduces leverage risk versus earlier peaks. Lower gross debt enhances negotiating leverage with partners and lenders and modestly reduces fixed financing costs, helping preserve cash for critical R&D activities.

Negative Factors

No revenue over multiple years

Absence of product revenue across multiple years means the company lacks operating cash generation and remains fully reliant on financing or partners. This structural revenue gap increases execution risk and constrains long-term sustainability until commercialization or licensing occurs.

Deeply negative shareholders' equity

Deep negative equity signals cumulative losses that impair solvency metrics and limit traditional financing options. Structural equity deficits can force dilutive recapitalizations or restrictive creditor terms, reducing strategic flexibility over the medium term.

Persistent cash burn and funding dependence

Consistent negative operating and free cash flow create ongoing dependency on external financing. Even with 2024 improvement, the structural need for capital raises heightens dilution risk, constrains multi-year planning, and may delay or complicate advancement of pivotal clinical programs.

Biophytis SA Business Overview & Revenue Model

Company Description

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

How the Company Makes Money

Biophytis SA Financial Statement Overview

Summary

Development-stage profile with no revenue (2020–2024) and persistent losses. While losses and cash burn improved meaningfully in 2024, the balance sheet is highly stressed with deeply negative equity and ongoing funding/dilution risk.

Income Statement

The company reports no revenue across 2020–2024, consistent with a pre-commercial biotech profile, but it also shows persistent and sizable operating losses. Losses have narrowed meaningfully versus 2021–2022 levels (EBIT and net loss improved into 2024), yet profitability remains far from breakeven and negative gross profit indicates ongoing operating cost pressure without offsetting product sales.

Balance Sheet

Financial position is strained: shareholders’ equity turned deeply negative by 2023–2024, which raises solvency and financing-risk concerns and makes leverage ratios less meaningful. Total debt remains material (about €9.8M in 2024) while total assets have declined sharply from 2020–2022 levels, suggesting reduced balance-sheet flexibility despite some debt reduction since 2022.

Cash Flow

Cash burn remains heavy, with operating cash flow and free cash flow negative every year. That said, burn improved materially in 2024 versus 2021–2023 (cash outflow narrowed), indicating better cost control. Free cash flow generally tracks net losses closely, but the business still depends on external funding until revenue generation or a step-change reduction in spending occurs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-357.00K	-298.00K	-803.00K	-484.00K	-311.00K	-280.00K
EBITDA	-6.82M	-8.26M	-13.80M	-25.52M	-26.50M	-13.66M
Net Income	-8.03M	-10.38M	-17.03M	-24.22M	-31.16M	-25.52M
Balance Sheet
Total Assets	6.62M	6.90M	11.96M	21.99M	36.26M	27.21M
Cash, Cash Equivalents and Short-Term Investments	1.21M	78.00K	5.57M	11.05M	25.16M	18.35M
Total Debt	7.77M	9.84M	8.27M	14.58M	17.55M	9.10M
Total Liabilities	14.44M	16.60M	15.85M	23.90M	30.56M	20.38M
Stockholders Equity	-7.78M	-9.67M	-3.86M	-1.88M	5.83M	2.30M
Cash Flow
Free Cash Flow	-2.68K	-8.64M	-13.09M	-19.13M	-24.14M	-10.08M
Operating Cash Flow	-3.69M	-8.64M	-12.87M	-18.99M	-23.80M	-9.86M
Investing Cash Flow	19.00K	10.00K	370.00K	-17.00K	12.16M	-12.71M
Financing Cash Flow	5.34M	3.14M	7.03M	6.13M	29.71M	21.95M

Biophytis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBPS	42 Neutral	€2.66M	-0.08	―	―	―	―